Dihydrotestosterone for use in androgenotherapy
US5648350A · kind A · utility
15Cited by
2References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 8, 1996 |
| Grant date | Jul 15, 1997 |
| Priority date | — |
| Expiry date | Jul 8, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/568
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to the administration of dihydrotestosterone (DHT) for preventing prostate cancer in male patients more than 50 years old and of reducing levels of plasma-borne sex hormone binding globulins (SHBG) in male patients having elevated levels thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.